<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611687</url>
  </required_header>
  <id_info>
    <org_study_id>P11-06/BF2.649</org_study_id>
    <secondary_id>2013-001506-29</secondary_id>
    <nct_id>NCT02611687</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period</brief_title>
  <official_title>Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multicenter double blind study is to assess efficacy and safety of&#xD;
      Pitolisant versus placebo in paediatric Narcoleptic patients with or without cataplexy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 6, 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of pitolisant in reducing residual Excessive Daytime Sleepiness (EDS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes in EDS measured by the Paediatric Daytime Sleepiness Scale (PDSS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of pitolisant in reducing the number of cataplectic episodes (for patients with cataplexy)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes in the average number of cataplexy episodes per weeks (recorded in sleep diary).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine safety in children and adolescents - Safety assessment will be done on monitoring of adverse events, physical examination, vital signs, ECG (QTc) and Blood Laboratory tests modifications and the mood appraisal</measure>
    <time_frame>8 weeks</time_frame>
    <description>Safety assessment will be done on monitoring of adverse events (Incidence of Treatment-Emergent Adverse Events), physical examination, vital signs (blood pressure and heart rate), ECG (QTc) and Blood Laboratory tests modifications (Haematology and Biochemistry) and the mood appraisal (Childhood Depression Inventory [CDI] and Columbia-Suicide Severity Rating Scale [C-SSRS]) throughout the study .</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Narcolepsy With Cataplexy</condition>
  <condition>Narcolepsy Without Cataplexy</condition>
  <arm_group>
    <arm_group_label>pitolisant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet, oral, once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>tablet, oral, once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pitolisant</intervention_name>
    <description>Tablet</description>
    <arm_group_label>pitolisant</arm_group_label>
    <other_name>BF2.649</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female children from 6 to less than 18 years of age suffering from narcolepsy&#xD;
             with or without cataplexy - ICSD-3 criteria (narcolepsy type 1 and 2).&#xD;
&#xD;
          -  PDSS&#xD;
&#xD;
          -  Patients should be free of non-authorized medication, in particular psychostimulant&#xD;
             treatments as from the screening visit onwards.&#xD;
&#xD;
          -  Parents - and patients old enough to understand who have expressed a willingness to&#xD;
             participate in the study, who have signed and dated the informed consent form prior to&#xD;
             beginning protocol required procedures.&#xD;
&#xD;
          -  In the opinion of the investigator, the patient must have adequate support to comply&#xD;
             with the entire study requirements as described in the protocol (e.g., transportation&#xD;
             to and from trial site, self rating scales and diaries completion, drug compliance,&#xD;
             scheduled visits, tests).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other conditions that can be considered the primary causes of EDS.&#xD;
&#xD;
          -  Cataplectic patients treated by anticataplectics which are not under a stable&#xD;
             treatment at the time of inclusion.&#xD;
&#xD;
          -  Patients treated for cataplexy or any other pathology, by tricyclic antidepressants.&#xD;
&#xD;
          -  Any significant abnormality of the electrocardiogram and particularly Fridericia's QTc&#xD;
             interval.&#xD;
&#xD;
          -  Patients with significant abnormality or clinical laboratory results.&#xD;
&#xD;
          -  Psychiatric and neurological disorders in the investigator's opinion, would preclude&#xD;
             the patient's participation and completion of this trial or comprise reliable&#xD;
             representation of subjective symptoms.&#xD;
&#xD;
          -  Active clinically significant illness, including unstable cardiovascular, endocrine,&#xD;
             neoplastic, gastrointestinal, haematological, hepatic, immunologic, metabolic,&#xD;
             neurological (other than narcolepsy/cataplexy), pulmonary, and/or renal disease which&#xD;
             could interfere with the study conduct or counter-indicate the study treatments or&#xD;
             place the patient at risk during the trial or compromise the study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Plazzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dipartimento di Scienze Biomediche e Neuromotorie Alma Mater Studiorum - Università di Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vitalmed Research Centre</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme-Mère-Enfant</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polikliniek Heemstede Neurologist-Somnologist</name>
      <address>
        <city>Heemstede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific-Research Medical Complex &quot;Your Health&quot;</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.M. Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V.M. Behterev National Medical Research Psychiatry and Neurology Center</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara Regional Clinical Hospital</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.I. Balaban Crimea Repiblic Clinical Psychiatric Hospital No. 1</name>
      <address>
        <city>Simferopol</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

